Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Immunocore Holdings plcNASDAQ: IMCR
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 4356.1% from a year ago
Other current liabilities stood at $207.39M at the end of Q1 FY2026, up 4356.1% from a year earlier and down 5.6% from the prior quarter. Over 3 fiscal years it compounded at +188.5% a year.
Context
- Other current liabilities amounted to 19.3% of total assets at the end of Q1 FY2026, up 18.9 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +4356.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 219.74M USD
- Year-over-year change
- +1577.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 219.74M | +1577.2% |
| FY2024 | 2024-12-31 | 13.1M | — |
| FY2023 | 2023-12-31 | 9.18M | +0.3% |
| FY2022 | 2022-12-31 | 9.15M | +10834.9% |
| FY2021 | 2021-12-31 | 83.68K | — |
Other Current Liabilities vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4356.1% is the highest of 10, against a peer median of -20.0%.
- Other current liabilities amounts to 19.3% of total assets for IMCR, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €481.4M EUR | +39.5% | -28.8% | 2.4% | |
| Mar 2026 | $207.39M USD | +4356.1% | +188.5% | 19.3% | |
| Jun 2026 | $27.36M USD | -45.6% | — | 3.8% | |
| Dec 2025 | A$26.47M AUD | +3458.3% | -47.1% | 18.0% | |
| Mar 2026 | $18.45M USD | — | -8.5% | 8.5% | |
| Jun 2026 | $12M USD | -25.0% | -27.9% | 1.3% | |
| Dec 2025 | €9.97M EUR | +30.4% | -19.4% | 15.9% | |
| Mar 2026 | €5.24M EUR | -20.0% | -46.0% | 1.0% | |
| Mar 2026 | $3.32M USD | -65.5% | -0.9% | 2.3% | |
| Mar 2026 | $2.25M USD | +21.4% | +33.3% | 0.2% | |
| Sep 2026 | $1.03M USD | -97.6% | +8.8% | 0.2% | |
| Peer median (excluding IMCR) | — | -20.0% | -19.4% | 2.3% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 321.06M | 402.47M | 350.27M | 455.73M | 467.71M |
| Short-term Investments | 0 | 0 | 0 | 364.65M | 396.44M |
| Net Receivables | 33.52M | 57.08M | 48.62M | 83.1M | 73.98M |
| Inventory | 0 | 692K | 3.56M | 5.45M | 6.74M |
| Other Current Assets | (7.69M) | 3.62M | 7.68M | 7.9M | 51.87M |
| Total Current Assets | 354.58M | 473.98M | 418.48M | 929.86M | 996.74M |
| Property, Plant & Equipment (Net) | 42.56M | 38.78M | 33.82M | 47.74M | 50.25M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 410 | 0 | 0 | 0 |
| Long-term Investments | 222.69K | 137K | 0 | 0 | 0 |
| Tax Assets | 3.48M | 5.12M | 8.68M | 14.79M | 0 |
| Other Non-current Assets | 6.44M | 8.75M | 11.45M | 17.12M | 20.28M |
| Total Non-current Assets | 52.7M | 52.79M | 53.96M | 79.64M | 70.53M |
| Total Assets | 407.28M | 526.76M | 472.44M | 1.01B | 1.07B |
| Account Payables | 10.12M | 14.45M | 14.08M | 25.1M | 24.36M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.01M |
| Tax Payables | 718.01K | 1.12M | 1.43M | 0 | 0 |
| Deferred Revenue | 33M | 7.76M | 0 | 0 | 583K |
| Other Current Liabilities | 83.68K | 9.15M | 9.18M | 13.1M | 219.74M |
| Total Current Liabilities | 82.57M | 100.84M | 110.01M | 212.18M | 246.7M |
| Long-term Debt | 50.24M | 47.81M | 37.99M | 391.01M | 393.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 8.65M | 5.24M | 4.36M | 5.43M | 4.86M |
| Other Non-current Liabilities | 76.93K | 2.22M | 773.94K | 0 | 0 |
| Total Non-current Liabilities | 93.19M | 87.02M | 70.54M | 436.61M | 439.54M |
| Total Liabilities | 175.76M | 187.86M | 180.55M | 648.79M | 686.24M |
| Common Stock | 118.77K | 129K | 83.18K | 135K | 136K |
| Retained Earnings | (649.7M) | (689.39M) | (589.3M) | (795.76M) | (831.28M) |
| Accumulated OCI | 521.31M | (54.67M) | (28.7M) | (33.76M) | (28.08M) |
| Other Stockholders Equity | 73.36M | 1K | 23.65K | 1K | 1K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 231.53M | 338.9M | 291.89M | 360.72M | 381.03M |
| Total Debt | 86.16M | 81.45M | 66.5M | 432.72M | 436.69M |
| Net Debt | (234.9M) | (321.02M) | (283.77M) | (23.01M) | (31.02M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.